All stock lists
Unlock the score
Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · Real-Time Price · USD
Healthcare · Biotechnology
87.63+1.85 (+2.16%)
Insider Score
/ 100
KOD Insider Score
Kodiak Sciences Inc. has a live Insider Score.
Scored on 82 qualifying trades from 1 insider in the last 90 days.
KOD analyst forecast
KOD analyst consensus
Moderate Buy4 ratings
Buy 4 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
KOD 12-month price target
$116.33+28.4% upsideaverage of 3 firms
$126.00High
$103.00Low
Best analysts covering KOD
- JP Morgan67%success rate · 3 calls
- Chardan Capital0%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
KOD analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-12 |
| H.C. Wainwright | — | $126.00 | +26.2% | — | 2026-10-12 | |
| Goldman Sachs | — | $103.00 | +13.0% | — | 2026-09-30 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-28 |
| — | LifeSci Capital | Outperform | — | — | Reiterated | 2026-09-28 |
| UBS | Buy | $120.00 | +33.5% | Reiterated | 2026-09-28 | |
| H.C. Wainwright | — | $96.00 | +8.1% | — | 2026-09-28 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-17 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-03 |
| — | Chardan Capital | Buy | — | — | Upgraded | 2026-05-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-27 |
| — | UBS | Buy | — | — | Reiterated | 2026-03-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-02-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-22 |
| — | Chardan Capital | Neutral | — | — | Reiterated | 2025-11-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-17 |
| — | HC Wainwright & Co. | Buy | — | — | Upgraded | 2025-11-11 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2025-10-24 |
| — | Chardan Capital | Neutral | — | — | Reiterated | 2025-10-06 |
| — | Barclays | Equal Weight | — | — | Upgraded | 2025-09-25 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-08-18 |
| — | Barclays | Underweight | — | — | Reiterated | 2025-08-14 |
| — | JP Morgan | Neutral | — | — | Upgraded | 2025-08-14 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-03-31 |
| — | Jefferies | Buy | — | — | Upgraded | 2024-12-09 |
| — | Barclays | Underweight | — | — | Reiterated | 2024-11-15 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-11-15 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2024-09-24 |
| — | UBS | Neutral | — | — | Reiterated | 2024-04-04 |
| — | Barclays | Underweight | — | — | Reiterated | 2024-04-01 |
| — | UBS | Neutral | — | — | Reiterated | 2023-12-21 |
| — | Capital One | Overweight | — | — | Upgraded | 2023-11-17 |
| — | UBS | Neutral | — | — | Downgraded | 2023-07-27 |
| — | JP Morgan | Underweight | — | — | Downgraded | 2023-07-25 |
| — | Barclays | Underweight | — | — | Reiterated | 2023-07-25 |
| — | Chardan Capital | Neutral | — | — | Downgraded | 2023-07-25 |
| — | Capital One | Equal Weight | — | — | Downgraded | 2023-07-24 |
| — | Jefferies | Hold | — | — | Downgraded | 2023-07-24 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2023-04-04 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-11-14 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-11-10 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-08-15 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2022-08-10 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-08-09 |
| — | Truist Securities | Buy | — | — | Reiterated | 2022-08-09 |
| — | Citigroup | Sell | — | — | Downgraded | 2022-08-02 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-05-24 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-05-17 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-05-11 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-04-12 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2022-02-24 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-02-24 |
| — | Citigroup | Neutral | — | — | Reiterated | 2022-02-24 |
| — | Barclays | Underweight | — | — | Reiterated | 2022-02-07 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2022-02-02 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-02-01 |
| — | Citigroup | Neutral | — | — | Reiterated | 2022-01-26 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-01-18 |
| — | Citigroup | Neutral | — | — | Reiterated | 2021-11-11 |
KOD earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-31 | -1.02 | -1.04 | $0 | $0 |
| 2026-05-07 | -0.93 | -0.94 | $0 | $0 |
| 2026-08-12 | -0.96 | -1.05 | $0 | $0 |
| 2026-11-12 | -1.06 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.